Rein Therapeutics, Inc. (NASDAQ:RNTX) Financings

Rein Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Announced: US$50M · US$1 a share · Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC
Dealers: Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC (lead)
Use of proceeds: Fully fund the Phase 2 trial of LTI-03 in IPF through completion, plus working capital and general corporate purposes
Apr 30, 2026
Pre-paid advances repayable in common stock
Announced: up to US$6M
Buyers: Yorkville Advisors Global, LP (affiliate) (up to $6 million in pre-paid advances, initial $1 million funded at signing)
Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes
Jul 30, 2025
Common stock under standby equity purchase agreement
Announced: up to US$15M
Buyers: Yorkville Advisors Global, LP (affiliate) (up to $15 million of common stock over 36 months at Rein's option)
Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes
Jul 30, 2025

Read by 6ix AI from the company's releases